Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

AORT

Artivion Inc

Dec 13 • 04:00PM ET

28.93

Dollar change -0.57
Percentage change -1.93	%

Healthcare • Medical Devices • USA • NYSE

Peers: MDT ABT EW SYK BSX ISRG ZBH TFX NVCR IART

| Held by: IJR IWM VTI VXF SPSM IWO IJT IHI SCHA IJS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.03	Insider Own	6.05%	Shs Outstand	41.91M	Perf Week	-2.46%
Market Cap	1.19B	Forward P/E	209.14	EPS next Y	0.14	Insider Trans	-2.25%	Shs Float	39.38M	Perf Month	6.32%
Income	-0.85M	PEG	-	EPS next Q	-0.07	Inst Own	86.83%	Short Float	8.52%	Perf Quarter	13.99%
Sales	384.90M	P/S	3.09	EPS this Y	101.11%	Inst Trans	2.24%	Short Ratio	14.06	Perf Half Y	25.13%
Book/sh	7.27	P/B	3.98	EPS next Y	1560.06%	ROA	-0.11%	Short Interest	3.35M	Perf Year	56.63%
Cash/sh	1.37	P/C	21.17	EPS next 5Y	2.00%	ROE	-0.30%	52W Range	16.48 - 30.45	Perf YTD	61.80%
Dividend Est.	-	P/FCF	108.12	EPS past 5Y	-57.58%	ROI	-0.15%	52W High	-4.99%	Beta	1.74
Dividend TTM	-	Quick Ratio	1.00	Sales past 5Y	6.52%	Gross Margin	60.41%	52W Low	75.50%	ATR (14)	0.87
Dividend Ex-Date	Dec 09, 2015	Current Ratio	1.55	EPS Y/Y TTM	96.62%	Oper. Margin	16.49%	RSI (14)	53.12	Volatility	3.62% 2.79%
Employees	1500	Debt/Eq	1.19	Sales Y/Y TTM	13.29%	Profit Margin	-0.22%	Recom	1.00	Target Price	33.17
Option/Short	Yes / Yes	LT Debt/Eq	0.85	EPS Q/Q	77.14%	Payout	-	Rel Volume	0.84	Prev Close	29.50
Sales Surprise	1.07%	EPS Surprise	21.01%	Sales Q/Q	9.02%	Earnings	Nov 07 AMC	Avg Volume	238.53K	Price	28.93
SMA20	0.69%	SMA50	4.64%	SMA200	17.19%	Trades		Volume	201,425	Change	-1.93%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-23-24	Initiated	JMP Securities	Mkt Outperform	$33
Sep-27-22	Reiterated	Lake Street	Buy	$32 → $28
Aug-08-22	Initiated	Lake Street	Buy	$32
Mar-03-22	Initiated	Stifel	Buy	$30

Dec-09-24 08:00AM	Artivion Granted FDA Humanitarian Device Exemption for the AMDS Hybrid Prosthesis (PR Newswire)
Nov-07-24 04:05PM	Artivion Reports Third Quarter 2024 Financial Results (PR Newswire)
Nov-05-24 04:15PM	Artivion to Participate in Upcoming Investor Conferences (PR Newswire) +5.56%
Oct-24-24 04:15PM	Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2024 Financial Results (PR Newswire)
Oct-10-24 04:10PM	Artivion Announces Presentation of Late-Breaking Clinical Data at the 38th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting (PR Newswire)
04:05PM	Loading…
Aug-08-24 04:05PM	Artivion Reports Second Quarter 2024 Financial Results (PR Newswire)
Aug-05-24 04:10PM	Artivion to Participate in Upcoming Investor Conferences (PR Newswire)
Jul-25-24 04:10PM	Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2024 Financial Results (PR Newswire)
Jul-03-24 08:00AM	3 Earnings All-Stars With More Room to Run (InvestorPlace)
Jul-01-24 04:05PM	Artivion Amends Agreements with Endospan (PR Newswire)
Jun-18-24 09:28AM	Do You Think Artivion (AORT) Stock Could Soar? (Insider Monkey)
May-08-24 09:15AM	Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Continue? (Zacks)
May-07-24 09:49AM	Artivion, Inc. (NYSE:AORT) Q1 2024 Earnings Call Transcript (Insider Monkey) +12.81%
May-06-24 05:20PM	Artivion (AORT) Tops Q1 Earnings and Revenue Estimates (Zacks)
04:05PM	Artivion Reports First Quarter 2024 Financial Results (PR Newswire)
08:05AM	Loading…
Apr-29-24 08:05AM	Artivion Announces Presentation of New Clinical Data for On-X Aortic Heart Valve and AMDS at the 104th American Association for Thoracic Surgery (AATS) Annual Meeting (PR Newswire)
Apr-22-24 04:10PM	Artivion Announces Release Date and Teleconference Call Details for First Quarter 2024 Financial Results (PR Newswire)
Apr-15-24 09:40AM	Is Artivion (AORT) Outperforming Other Medical Stocks This Year? (Zacks)
Apr-01-24 04:10PM	Artivion to Participate in the 23rd Annual Needham Virtual Healthcare Conference (PR Newswire)
Mar-29-24 09:15AM	Artivion, Inc. (AORT) Hits Fresh High: Is There Still Room to Run? (Zacks)
Mar-28-24 09:40AM	Are Medical Stocks Lagging Artivion (AORT) This Year? (Zacks)
Mar-12-24 09:40AM	Is Artivion (AORT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-06-24 04:10PM	Artivion to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference (PR Newswire)
Feb-22-24 09:40AM	Is Artivion (AORT) Outperforming Other Medical Stocks This Year? (Zacks)
09:15AM	Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Continue? (Zacks)
Feb-21-24 09:55AM	Wall Street Analysts Think Artivion (AORT) Could Surge 30.7%: Read This Before Placing a Bet (Zacks)
Feb-16-24 10:39AM	Artivion, Inc. (NYSE:AORT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-15-24 04:05PM	Artivion Reports Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
Feb-01-24 04:10PM	Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
Jan-29-24 08:25AM	Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 60th Society of Thoracic Surgery Annual Meeting (PR Newswire)
04:05PM	Loading…
Jan-18-24 04:05PM	Artivion Obtains $350 Million in Senior Secured Credit Facilities (PR Newswire)
Dec-06-23 04:15PM	Artivion Appoints Lance A. Berry as Executive Vice President, Chief Financial Officer; Announces Retirement of D. Ashley Lee, Chief Financial Officer (PR Newswire)
Nov-09-23 08:25AM	Artivion Announces Completion of Enrollment in PERSEVERE Trial (PR Newswire)
Nov-08-23 04:05PM	Artivion to Participate in Upcoming Investor Conferences (PR Newswire)
Nov-02-23 04:05PM	Artivion Reports Third Quarter 2023 Financial Results (PR Newswire) +9.88%
Oct-19-23 04:10PM	Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2023 Financial Results (PR Newswire)
Oct-05-23 04:15PM	Artivion Announces Presentation of Real World Data from Post Market Study of On-X Aortic Heart Valve Replacement Patients Treated with Low Dose Warfarin (PR Newswire) +7.71%
04:05PM	Artivion Announces Presentation of Late-Breaking Interim Data from AMDS PERSEVERE Trial at the 37th European Association for Cardio-Thoracic Surgery Annual Meeting (PR Newswire)
Sep-26-23 08:25AM	Artivion to Present at the Deutsche Bank 31st Annual Leveraged Finance Conference (PR Newswire)
Sep-14-23 08:05AM	Artivion to Present at the Gilmartin Group Emerging Growth Company Showcase (PR Newswire)
Aug-31-23 09:55AM	Wall Street Analysts Believe Artivion (AORT) Could Rally 44.41%: Here's is How to Trade (Zacks)
Aug-10-23 09:55AM	Does Artivion (AORT) Have the Potential to Rally 52.78% as Wall Street Analysts Expect? (Zacks)
Aug-03-23 04:05PM	Artivion Reports Second Quarter 2023 Financial Results (PR Newswire)
Aug-01-23 08:25AM	Artivion to Participate in Upcoming Investor Conferences (PR Newswire)
Jul-20-23 08:25AM	Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2023 Financial Results (PR Newswire)
Jun-21-23 08:00PM	AORT: What does Argus have to say about AORT? (Argus Research)
May-23-23 08:04AM	Artivion Announces FDA PMA Approval of PerClot and Transfer of PMA to Baxter (PR Newswire)
May-04-23 04:05PM	Artivion Reports First Quarter 2023 Financial Results (PR Newswire) +13.78%
Apr-26-23 08:00PM	AORT: What does Argus have to say about AORT? (Argus Research)
Apr-20-23 04:10PM	Artivion Announces Release Date and Teleconference Call Details for First Quarter 2023 Financial Results (PR Newswire)
Apr-10-23 04:10PM	Artivion to Participate in the 22nd Annual Needham Virtual Healthcare Conference (PR Newswire)
Mar-06-23 04:10PM	Artivion to Participate in the Oppenheimer 33rd Annual Healthcare Conference (PR Newswire) -7.10%
Feb-16-23 04:05PM	Artivion Reports Fourth Quarter and Full Year 2022 Financial Results (PR Newswire) +5.76%
Feb-02-23 08:30AM	Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2022 Financial Results (PR Newswire) +7.46%
Nov-25-22 12:00PM	Artivion (AORT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:55AM	Wall Street Analysts Think Artivion (AORT) Could Surge 79%: Read This Before Placing a Bet (Zacks)
Nov-09-22 09:55AM	Wall Street Analysts Predict a 173% Upside in Artivion (AORT): Here's What You Should Know (Zacks)
Nov-08-22 04:25PM	Artivion to Participate in Upcoming Investor Conferences (PR Newswire)
Nov-03-22 04:05PM	Artivion Reports Third Quarter 2022 Financial Results (PR Newswire)
Oct-20-22 08:25AM	Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2022 Financial Results (PR Newswire)
Sep-29-22 04:10PM	Elizabeth Hoff Joins Artivion Board of Directors (PR Newswire)
Sep-23-22 07:00AM	Artivion Follows Recommendation to Stop PROACT Xa Clinical Trial (PR Newswire) -28.05%
Sep-14-22 08:10AM	Artivion to Present at the Deutsche Bank 30th Annual Leveraged Finance Conference (PR Newswire)
Sep-06-22 04:10PM	Artivion to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-24-22 04:10PM	Artivion to Present at the Gilmartin Group Emerging Growth Company Showcase (PR Newswire)
Aug-04-22 04:05PM	Artivion Reports Second Quarter 2022 Financial Results (PR Newswire)
Aug-03-22 08:25AM	Artivion to Participate in Upcoming Investor Conferences (PR Newswire)
Jul-29-22 12:00PM	What Makes Artivion (AORT) a New Buy Stock (Zacks)
Jul-27-22 08:25AM	Artivion Initiates Enrollment in PERSEVERE Clinical Trial (PR Newswire)
Jul-21-22 08:25AM	Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2022 Financial Results (PR Newswire)
May-16-22 08:25AM	Artivion to Participate in the UBS 2022 Global Healthcare Conference (PR Newswire) +5.06%
May-12-22 02:55PM	Further weakness as Artivion (NYSE:AORT) drops 24% this week, taking three-year losses to 48% (Simply Wall St.)
May-05-22 04:05PM	Artivion Reports First Quarter 2022 Financial Results (PR Newswire) -7.44%
Apr-21-22 08:25AM	ArtivionAnnounces Release Date and Teleconference Call Details for First Quarter 2022 Financial Results (PR Newswire)
Mar-31-22 08:25AM	Artivion to Participate in the 21st Annual Needham Virtual Healthcare Conference (PR Newswire)
Mar-27-22 02:33PM	Are Institutions Heavily Invested In Artivion, Inc.'s (NYSE:AORT) Shares? (Simply Wall St.)
Mar-14-22 04:10PM	Artivion Publishes Inaugural Corporate Responsibility Report (PR Newswire)
Mar-10-22 12:48PM	Thermo Fisher Scientific (Finance I) B.V. -- Moody's announces completion of a periodic review for a group of North America Medical Products and Device issuers (Moody's)
12:17PM	Danaher Corporation -- Moody's announces completion of a periodic review for a group of North America Medical Products and Device issuers (Moody's)
Mar-09-22 08:15AM	Artivion to Host Investor & Analyst Day on March 23, 2022 (PR Newswire)
Mar-03-22 04:05PM	Artivion to Participate in the Oppenheimer 32nd Annual Healthcare Conference (PR Newswire)
Feb-17-22 04:05PM	Artivion Reports Fourth Quarter and Full Year 2021 Financial Results (PR Newswire)
Feb-03-22 08:05AM	Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2021 Financial Results (PR Newswire)
Jan-31-22 08:05AM	Artivion Announces Publication of On-X® Mitral Heart Valve PROACT Study Results in The Annals of Thoracic Surgery (PR Newswire)

Artivion, Inc. engages in the research and development of solutions which address cardiac and vascular surgeons' clinical challenges in treating patients with aortic diseases. Its products include aortic stents and stent grafts, prosthetic heart valves, cryopreserved cardiac and vascular allografts, and surgical sealants. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes aortic stents and stent grafts, surgical sealants, and On-X products. The Preservation Services segment offers cardiac and vascular tissue preservation services. The company was founded on January 19, 1984, and is headquartered in Kennesaw, GA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Holloway Jean F	Officer	Dec 12 '24	Proposed Sale	30.25	4,011	121,333		Dec 12 05:04 PM
Holloway Jean F	SVP, General Counsel	Dec 11 '24	Sale	30.12	8,070	243,109	153,862	Dec 12 04:11 PM
Holloway Jean F	Officer	Dec 11 '24	Proposed Sale	30.12	8,070	243,109		Dec 11 04:59 PM
Horton Amy	VP, Chief Accounting Officer	Dec 06 '24	Sale	29.66	4,329	128,398	135,660	Dec 09 03:34 PM
GREEN ANDREW M	VP Regulatory	Dec 04 '24	Sale	30.00	7,618	228,540	33,503	Dec 04 04:11 PM
ANDREW GREEN	Officer	Dec 04 '24	Proposed Sale	30.00	7,618	228,540		Dec 04 04:02 PM
Horton Amy	VP, Chief Accounting Officer	Oct 01 '24	Option Exercise	21.55	12,430	267,866	152,419	Oct 02 06:44 PM
Horton Amy	VP, Chief Accounting Officer	Oct 01 '24	Sale	26.18	12,430	325,415	139,989	Oct 02 06:44 PM
AMY HORTON	Officer	Oct 01 '24	Proposed Sale	26.18	12,430	325,414		Oct 01 04:25 PM
Holloway Jean F	SVP, General Counsel	Aug 26 '24	Sale	26.55	3,167	84,096	161,932	Aug 27 04:47 PM
Holloway Jean F	Officer	Aug 26 '24	Proposed Sale	26.55	3,167	84,084		Aug 26 05:08 PM
Getz Matthew A	VP, Human Resources	Aug 16 '24	Sale	25.31	9,420	238,434	34,116	Aug 19 04:58 PM
Getz Matthew A	Officer	Aug 16 '24	Proposed Sale	25.30	9,895	250,344		Aug 16 04:44 PM
Holloway Jean F	SVP, General Counsel	Aug 15 '24	Sale	25.76	2,383	61,393	165,099	Aug 16 11:38 AM
Holloway Jean F	Officer	Aug 15 '24	Proposed Sale	25.76	2,383	61,393		Aug 15 05:30 PM
SEMEDO ANTHONY B.	Director	Aug 13 '24	Sale	24.99	9,709	242,628	34,159	Aug 15 10:37 AM
Anthony Semedo	Director	Aug 13 '24	Proposed Sale	24.89	9,709	241,650		Aug 13 02:33 PM
Holloway Jean F	SVP, General Counsel	May 10 '24	Sale	23.42	1,250	29,275	167,482	May 13 06:05 PM
Holloway Jean F	SVP, General Counsel	May 09 '24	Sale	23.79	979	23,286	168,732	May 10 05:12 PM
Stanton Marshall S.	SVP, Clinical & MD Affair	Mar 20 '24	Sale	20.39	2,183	44,511	83,296	Mar 21 05:14 PM
GREEN ANDREW M	VP Regulatory	Mar 15 '24	Sale	20.00	1,462	29,240	41,121	Mar 18 06:09 PM
GREEN ANDREW M	VP Regulatory	Mar 14 '24	Sale	20.00	3,994	79,880	42,583	Mar 15 05:20 PM
Getz Matthew A	VP, Human Resources	Mar 12 '24	Sale	19.94	5,000	99,720	43,536	Mar 14 09:06 PM
Mackin James P	President & CEO	Mar 05 '24	Sale	18.72	13,996	262,037	705,562	Mar 07 06:20 PM
Holloway Jean F	SVP, General Counsel	Mar 05 '24	Sale	18.72	2,380	44,559	169,669	Mar 07 06:16 PM
Davis John E	Chief Commercial Officer	Mar 05 '24	Sale	18.72	2,022	37,856	165,637	Mar 07 06:14 PM
Getz Matthew A	VP, Human Resources	Mar 05 '24	Sale	18.72	1,157	21,661	48,503	Mar 07 06:12 PM
Maney Rochelle L.	VP, Quality	Mar 05 '24	Sale	18.72	1,157	21,662	46,536	Mar 07 06:10 PM
GREEN ANDREW M	VP Regulatory	Mar 05 '24	Sale	18.72	1,160	21,718	46,541	Mar 07 06:07 PM
Stanton Marshall S.	SVP, Clinical & MD Affair	Mar 05 '24	Sale	18.72	1,506	28,195	85,438	Mar 07 06:05 PM
Horton Amy	VP, Chief Accounting Officer	Mar 05 '24	Sale	18.72	1,152	21,568	139,957	Mar 07 06:01 PM
Tyrs Florian	VP, Global Operations	Feb 27 '24	Sale	19.83	339	6,724	21,558	Feb 29 05:43 PM
Horton Amy	VP, Chief Accounting Officer	Feb 27 '24	Sale	19.83	325	6,446	137,531	Feb 29 05:39 PM
Mackin James P	President & CEO	Feb 27 '24	Sale	19.83	4,837	95,939	690,940	Feb 29 05:36 PM
Holloway Jean F	SVP, General Counsel	Feb 27 '24	Sale	19.83	485	9,620	166,325	Feb 29 05:34 PM
Davis John E	Chief Commercial Officer	Feb 27 '24	Sale	19.83	584	11,583	161,935	Feb 29 05:32 PM
Maney Rochelle L.	VP, Quality	Feb 27 '24	Sale	19.83	370	7,339	44,115	Feb 29 05:30 PM
Getz Matthew A	VP, Human Resources	Feb 27 '24	Sale	19.83	325	6,446	46,082	Feb 29 05:27 PM
GREEN ANDREW M	VP Regulatory	Feb 27 '24	Sale	19.83	421	8,350	44,123	Feb 29 05:21 PM
Stanton Marshall S.	SVP, Clinical & MD Affair	Feb 27 '24	Sale	19.83	465	9,223	81,220	Feb 29 05:18 PM
Mackin James P	President & CEO	Feb 26 '24	Sale	20.27	31,312	634,729	650,297	Feb 28 05:22 PM
Holloway Jean F	SVP, General Counsel	Feb 26 '24	Sale	20.27	2,880	58,381	155,540	Feb 28 05:18 PM
Maney Rochelle L.	VP, Quality	Feb 26 '24	Sale	20.27	2,315	46,928	39,197	Feb 28 05:16 PM
Davis John E	Chief Commercial Officer	Feb 26 '24	Sale	20.27	3,514	71,233	151,687	Feb 28 05:12 PM
Getz Matthew A	VP, Human Resources	Feb 26 '24	Sale	20.27	2,313	46,887	40,123	Feb 28 05:07 PM
GREEN ANDREW M	VP Regulatory	Feb 26 '24	Sale	20.27	2,403	48,711	38,848	Feb 28 05:04 PM
Stanton Marshall S.	SVP, Clinical & MD Affair	Feb 26 '24	Sale	20.27	3,048	61,786	72,489	Feb 28 05:01 PM
Tyrs Florian	VP, Global Operations	Feb 26 '24	Sale	20.27	893	18,103	21,897	Feb 28 04:58 PM
Holloway Jean F	SVP, General Counsel	Feb 20 '24	Sale	18.86	3,527	66,537	131,858	Feb 22 05:37 PM
Horton Amy	VP, Chief Accounting Officer	Feb 20 '24	Sale	18.86	1,695	31,976	122,345	Feb 22 05:35 PM
Davis John E	Chief Commercial Officer	Feb 20 '24	Sale	18.86	2,556	48,219	128,177	Feb 22 05:32 PM
Maney Rochelle L.	VP, Quality	Feb 20 '24	Sale	18.86	407	7,678	29,123	Feb 22 05:29 PM
Getz Matthew A	VP, Human Resources	Feb 20 '24	Sale	18.86	1,695	31,976	28,692	Feb 22 05:26 PM
Tyrs Florian	VP, Global Operations	Feb 20 '24	Sale	18.86	249	4,697	16,253	Feb 22 05:22 PM
Mackin James P	President & CEO	Feb 20 '24	Option Exercise	16.30	59,225	965,368	611,105	Feb 22 05:08 PM
Mackin James P	President & CEO	Feb 20 '24	Sale	18.85	72,069	1,358,818	539,036	Feb 22 05:08 PM
Holloway Jean F	SVP, General Counsel	Jan 02 '24	Option Exercise	16.30	21,229	346,033	154,749	Jan 04 04:25 PM
Holloway Jean F	SVP, General Counsel	Jan 02 '24	Sale	18.00	21,229	382,122	133,520	Jan 04 04:25 PM
Davis John E	Senior VP, Global Sales	Jan 02 '24	Option Exercise	16.30	13,562	221,061	142,295	Jan 04 04:22 PM
Davis John E	Senior VP, Global Sales	Jan 02 '24	Sale	18.00	13,562	244,116	128,733	Jan 04 04:22 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AORT

Artivion Inc

Upgrade your FINVIZ experience